Phase II Clinical Study on the GEMOX Regimen as Secondline Therapy for Advanced Ovarian Cancer

Aim: To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plusoxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer.
Methods: 64 patients withadvanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases).The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m2 with afixed-dose rate of 10 mg/m2/min, on days 1 and 8 and oxaliplatin at 100 mg/m2 on day 1, IVGTT, repeated every3 weeks. The control group was treated with intravenous infusion of gemcitabine at 1000 mg/m2 within 30 minon days 1 and and oxaliplatin at 100 mg/m2 on day 1, IVGTT, again repeated every 3 weeks. CT scans or MRIwere used for review every 1-2 cycles.
Results: The effective rate in the experimental group was significantly highthan control group (43.2% vs 35.0%; P < 0.05), with no obvious difference of hematologic or non-hematologictoxicity between the two groups (P > 0.05).
Conclusion: GEMOX regimen is very effective to treat advancedovarian cancer, with low toxicity, good tolerance and improved life quality in patients.